Research Output per year
Fingerprint Dive into the research topics where Pamela Maxwell is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 51 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
A gene signature associated with PTEN activation defines good prognosis intermediate-risk prostate cancer cases
Ong, C. W., Maxwell, P., Alvi, M. A., McQuaid, S., Waugh, D., Mills, I. & Salto-Tellez, M., 28 Feb 2018, In : The Journal of Pathology: Clinical Research.Research output: Contribution to journal › Article
Open Access
File
3
Citations
(Scopus)
214
Downloads
(Pure)
Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists
McCann, C., Crawford, N., Majkut, J., Holohan, C., Armstrong, C., Maxwell, P., Ong, C. W., LaBonte Wilson, M., McDade, S., Waugh, D. & Longley, D., 22 Oct 2018, In : Cell, Death & Disease. 9, 1081, 13 p., 1081.Research output: Contribution to journal › Article
Open Access
File
3
Citations
(Scopus)
172
Downloads
(Pure)
Radio-resistance of PTEN-deficient prostate tumours is enhanced by treatment-induced chemokine signalling and is associated with biochemical recurrence and development of metastasis.
Armstrong, C., Coulter, J., Ong, C. W., Maxwell, P., Butterworth, K., Oksana, L., Berlingeri, S., LaBonte Wilson, M., Walker, S., O'Sullivan, J., Salto-Tellez, M., Jain, S., Mills, I., Illidge, T., Kennedy, R., Prise, K. & Waugh, D., 01 Aug 2018.Research output: Contribution to conference › Poster
Enhanced radio-sensitivity of PTEN-deficient prostate tumours mediated by inhibition of intrinsic and treatment-potentiated CXC-chemokine signaling
Armstrong, C., Coulter, J., Ong, C. W., Maxwell, P., LaBonte Wilson, M., Butterworth, K., Lyubomska, O., Berlingeri, S., Gallagher, R., Walker, S., O'Sullivan, J., Mills, I., Salto-Tellez, M., Illidge, T., Bristow, R. G., Kennedy, R., Prise, K. & Waugh, D., 2017.Research output: Contribution to conference › Poster
Enzalutamide-induced hypoxia attenuates response and promotes resistance in pre-clinical models of prostate cancer.
Maxwell, P., McKechnie, M., Armstrong, C., Ong, C. W., Waugh, D. & LaBonte Wilson, M., 2017.Research output: Contribution to conference › Poster